Allianz Asset Management GmbH decreased its stake in shares of Qiagen NV (NASDAQ:QGEN) by 9.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 175,696 shares of the company’s stock after selling 18,420 shares during the period. Allianz Asset Management GmbH owned approximately 0.08% of Qiagen worth $5,534,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Acrospire Investment Management LLC boosted its stake in shares of Qiagen by 11.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock valued at $112,000 after purchasing an additional 349 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its position in Qiagen by 0.5% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 3,961 shares of the company’s stock valued at $133,000 after acquiring an additional 20 shares during the period. Quadrant Capital Group LLC lifted its position in Qiagen by 4.1% during the 2nd quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock valued at $183,000 after acquiring an additional 225 shares during the period. Koch Industries Inc. purchased a new position in Qiagen during the 2nd quarter valued at about $231,000. Finally, Hartford Investment Management Co. purchased a new position in Qiagen during the 3rd quarter valued at about $231,000. 62.09% of the stock is currently owned by hedge funds and other institutional investors.
QGEN has been the subject of several research reports. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Qiagen in a report on Tuesday, November 7th. Commerzbank reissued a “buy” rating on shares of Qiagen in a report on Wednesday. Evercore ISI assumed coverage on shares of Qiagen in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $35.00 target price for the company. BidaskClub upgraded shares of Qiagen from a “sell” rating to a “hold” rating in a research report on Wednesday, December 20th. Finally, Zacks Investment Research lowered shares of Qiagen from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. Qiagen currently has a consensus rating of “Hold” and a consensus target price of $34.63.
Qiagen (NASDAQ:QGEN) last released its quarterly earnings results on Monday, November 6th. The company reported $0.32 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.32. The company had revenue of $364.00 million for the quarter, compared to the consensus estimate of $363.42 million. Qiagen had a net margin of 6.40% and a return on equity of 11.36%. Qiagen’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.29 earnings per share. sell-side analysts anticipate that Qiagen NV will post 1.25 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Qiagen NV (NASDAQ:QGEN) Shares Sold by Allianz Asset Management GmbH” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://stocknewstimes.com/2018/01/11/allianz-asset-management-gmbh-reduces-stake-in-qiagen-nv-qgen.html.
Qiagen Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.